{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:52Z","timestamp":1791414652474,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.canlet.2006.09.006","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T15:29:34Z","timestamp":1161790174000},"page":"271-282","source":"Crossref","is-referenced-by-count":199,"title":["5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency"],"prefix":"10.1016","volume":"249","author":[{"given":"M.","family":"Boisdron-Celle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Remaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gamelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gamelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2006.09.006_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.canlet.2006.09.006_bib2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a french intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2006.09.006_bib3","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1200\/JCO.2003.10.065","article-title":"Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial","volume":"21","author":"Andre","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2006.09.006_bib4","first-page":"2672","article-title":"Dihydropyrimidine dehydrogenase: its role in 5-Fluorouracil clinical toxicity and tumor resistance","volume":"5","author":"Diasio","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib5","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2006.09.006_bib6","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2006.09.006_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase (biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity)","volume":"81","author":"Diasio","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2006.09.006_bib9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1998.16.4.1470","article-title":"Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients","volume":"16","author":"Gamelin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2006.09.006_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","article-title":"Relationship between 5-fluorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU containing infusional therapy","volume":"77","author":"Gamelin","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2006.09.006_bib11","unstructured":"A.H. Van Gennip, E.J. Van Bree-Blom, S.K. Wadman, et al., HPLC of urinary pyrimidines for the evaluation of primary and secondary abnormalities of pyrimidine metabolism. in: Hawk G.L. (Ed.), Biological Biomedical Applications of Liquid Chromatography, III. New York and Basel, Marcel Dekker Inc., 1982, pp 285\u2013296."},{"key":"10.1016\/j.canlet.2006.09.006_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2006.09.006_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.canlet.2006.09.006_bib14","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.canlet.2006.09.006_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","article-title":"Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency","volume":"40","author":"Van Kuilenburg","year":"2003","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.canlet.2006.09.006_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00008571-199812000-00001","volume":"8","author":"Mc Leod","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.canlet.2006.09.006_bib18","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-Fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"Van Kuilenburg","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD allelas do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.canlet.2006.09.006_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","article-title":"The uracil Breath test in the assessment of dihydropryrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C] dihydrouracil","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0378-4347(97)00211-9","article-title":"Rapid and sensitive HPLC analysis of halogenopyrimidines in plasma","volume":"695","author":"Gamelin","year":"1997","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.canlet.2006.09.006_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.canlet.2006.09.006_bib23","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","article-title":"Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients","volume":"10","author":"Rouits","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2006.09.006_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2005.11.008","article-title":"Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype","volume":"242","author":"Barbado","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2006.09.006_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation","volume":"101","author":"Van Kuilenburg","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2006.09.006_bib27","first-page":"4705","article-title":"Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"Van Kuilenburg","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008571-200203000-00007","article-title":"A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms","volume":"12","author":"Mattison","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.canlet.2006.09.006_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s004390050502","article-title":"Identification of a four-base deletion (delTCAT296-299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression","volume":"100","author":"Vreken","year":"1997","journal-title":"Hum. Genet."},{"key":"10.1016\/j.canlet.2006.09.006_bib30","first-page":"2999","article-title":"Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a japanese patient with 5-Fluorouracil toxicity","volume":"4","author":"Kouwaki","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s004390050637","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W","volume":"101","author":"Vreken","year":"1997","journal-title":"Hum. Genet."},{"key":"10.1016\/j.canlet.2006.09.006_bib32","first-page":"4705","article-title":"Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"Van Kuilenburg","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/bbrc.2000.2593","article-title":"Cloning and initial characterization of the human DPYD gene promoter","volume":"271","author":"Collie-Duguid","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2006.09.006_bib34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1101\/gr.10.8.1249","article-title":"Determination of single-nucleotide polymorphism by real-time pyrophosphate DNA sequencing","author":"Alderborn","year":"2000","journal-title":"Genome Res."},{"key":"10.1016\/j.canlet.2006.09.006_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1101\/gr.11.1.3","article-title":"Pyrosequencing sheds light on DNA sequencing","volume":"11","author":"Ronaghi","year":"2001","journal-title":"Genome. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383506005362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383506005362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T00:25:31Z","timestamp":1555892731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383506005362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0304383506005362"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2006.09.006","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}